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** ABSTRACT: 
 
 
The pharmaceutical industry is a growing environment which seems to expand along-
side globalization. External sources of ideas support open innovation for the initiation 
of the drug development process. Open innovation has shown to distinguish a firm 
from competitors. Further exploration of the methods involved in managing drug re-
search and development provides insight into the success of modern innovative ap-
proaches for developing drugs.  
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I. INTRODUCTION 
 
 
The Bio-pharmaceutical industry is growing intensively. Alongside demand, competi-
tion between firms is highly responsible for the increasingly growing industry. 
Growth often comes as a consequence of negative occurrences which prove the ne-
cessity for new methods and approaches. Just as in the complex drug development 
process, which over time became strictly regulated and improved, pharmaceutical 
companies are noticing the importance of acquiring external sources of information, 
knowledge and ideas in order to perfect and expand their line of success. Research 
and development departments within companies are of significant value as this con-
cept of open innovation grows. The possibilities of a company are less limited when 
searching outside of its own boundaries. 
Chesbrough and Inauen & Schenker-Wicki highlight the large amount of external 
sources contributing to the concept of open innovation.  Adapting to a growing envi-
ronment with such a concept requires a new form of management which can transit 
from processing only internal information to processing the vast amount of external 
knowledge which is now available when adopting such a method as open innovation. 
Hyunju & Phillips emphasize the importance of networking management both exter-
nally and internally in the firm. The more experience a firm has with processing 
knowledge and managing external sources, the higher the usefulness of the infor-
mation, which has show to be equally proportional to chances of success.  
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PROBLEM FORMULATION 
 
 
 
IN THE PHARMACEUTICAL INDUSTRY, HOW ARE OUTSIDE SOURCES CONTRIBUTING TO 
OPEN INNOVATION OF DRUG DEVELOPMENT? 
 
 
  
Spring 2015: Minna Munch- Jensen and Ursula Izabel Waltemath 
7 
 
II. BACKGROUND INFORMATION 
 
Introduction to crowdsourcing 
The term crowdsourcing stems from an article in the magazine Wired by Jeff Howe 
“The Rise of Crowdsourcing” (Howe, 2006). In this article Howe enumerates differ-
ent examples of early crowdsourcing (Howe, 2006). This ranges from Amazon.com to 
iStockphoto, all internet-based companies that rely on user interaction (Howe, 2006). 
The term, crowdsourcing, which Howe coined in his article, has since been heavily 
developed by researchers, and could fill a whole project by itself. Here follows there-
for a small introduction to crowdsourcing, and its relation to web 2.0 (Howe,2006) 
(Kleeman et al., 2008). This again relates to open innovation, in that it builds on the 
same ideas of open sharing and dialogue (Kleeman et al., 2008; p. 20). 
 
Crowdsourcing 
Crowdsourcing is an offshoot of the so-called web 2.0, which is a term coined after 
the dot-com bubble in the autumn of 2001 (O’Reilly, 2007).  A precise definition of 
what Web 2.0 is, is difficult to come by, but one of its characteristics is the term col-
lective knowledge, or the so-called ‘crowd’ who’s role is described as follows: 
     ” As users add new content, and new sites, it is bound in to the struc-
ture of the web by other users discovering the content and linking to it. Much as syn-
apses form in the brain, with associations becoming stronger through repetition or 
intensity, the web of connections grows organically as an output of the collective ac-
tivity of all web users”  
    (O´Reilly, 2007, p. 6). 
On the basis of this new understanding, and usage of the World Wide Web, Howe 
introduces the word crowdsourcing, as opposed to outsourcing (Howe, 2006). This 
term has since been redeveloped and Kleeman et al defines: 
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 ”Crowdsourcing takes place when a profit oriented firm outsources spe-
cific tasks essential for the making or sale of its product to the general public (the 
crowd) in the form of an open call over the internet, with the intention of animating 
individuals to make a (voluntary) contribution to the firm´s production process for 
free or for significantly less than that contribution is worth to the firm.” 
    (Kleeman et al, 2008, p. 6) 
There are many examples of crowdsourcing, such as Wikipedia, Flikr, Youtube etc. 
(Kleeman et al., 2008). Kleemans et al, lists 7 different types of crowdsourcing, all of 
them have inherent in them the usage of the crowd, and the goal of commercializing 
the knowledge of the crowd (Kleeman et al, 2008) 
Table 1. (Kleeman et al, 2008) 
Type of Crowdsourcing Description 
Paticipation of consumers in product develop-
ment and configuration 
Companies ask for comments and suggestions 
on current and future products 
Product design Companies ask to develop a whole new product 
from A to Z 
Competitive bids on specifically defined tasks 
or problems 
Companies ask to give a solution to unsolved 
problems 
Permanent open calls Companies ask for any new information or doc-
umentation 
Community reporting Same as before apart that the work is done by a 
known community instead 
Product rating by consumers and consumer pro-
filing 
Companies ask for product reviews and opin-
ions for other users to see  
Customer-to-customer support Companies ask customers to help other custom-
ers and use it for consumer knowledge and 
product design 
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What Kleeman et al, focuses heavily on in their article, is what is in it for the consum-
ers/contributors when they spend their time and resources on a problem that gives 
them no benefits (Kleeman et al, 2008). Kleeman et al brings to types of motivations 
in to play, the extrinsic and the intrinsic. Extrinsic motivation is the motivation fueled 
by the prospect of monetary gains, professional gain, or gain of knowledge (Kleeman 
et al, 2008). Intrinsic motivation is the wish to engage in projects for no other reason 
than ‘the fun of it’ (Kleeman et al, 2008).  
Kleeman cites studies for having found, that the greatest motivating factor for a per-
son to partake in activities like crowdsourcing, is the intrinsic motivation (Kleeman et 
al, 2008). 
 
1. INNOVATION 
A) Open Innovation 
Open innovation as a theoretical term stems from experiences connected with the de-
velopment of open-source software (Elquist et al, 2009).  In the beginning most re-
search emphasis was placed on open innovation in high-tech companies, but the scope 
has since been broadened (Elmquist et al, 2009).  
Henry Chesbrough first coined the expression Open Innovation in his 2003 book 
“Open Innovation: The New Imperative for Creating and Profiting from Technolo-
gy”( Elmquist et al, 2009). In this he argues: 
 “(…) that companies in the twentieth century have invested heavily in 
internal R&D and hiring the best people – enabling them to develop the most innova-
tive ideas and protect them with intellectual property (IP) strategies. The generated 
profit was used to reinvest in R&D –a virtuous circle of innovation. However, at the 
end of the twentieth century, a number of factors have changed, causing the innova-
tion process in the firms to start breaking up”  
    (Elmquist et al, 2009, p.328). 
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Chesbrough presented the model of open innovation, where companies could com-
mercialize ideas and patens both externally and internally by using new routes to the 
marked.  
 “In an open innovation process, projects go to the marked in many 
ways, such as out-licensing or a spin-off venture in addition to traditional sales chan-
nels. Open innovation is also described as ‘both a set of practices for profiting from 
innovation and a cognitive model for creating, interpreting and researching from those 
practices’”  
    (Elmquist et al, 2009, p. 329). 
Chesbrough have been analyzing the shifting world of R&D, where great changes 
have been underway (Chesbrough, 2003). What he found, was that the importance of 
a big R&D department was dwindling, and successful start-ups was gaining marked 
shares by acquiring ideas by external sources (Chesbrough, 2003).  
This was a great change, for many years it was hold to be a truth that the company 
that invested most heavily in R&D was the company that got to the marked first 
(Chesbrough, 2003). Innovation was thought of as a virtuous circle where the compa-
ny invested in R&D, hired the best employees, which led the company to invent the 
best ideas, and therefore “win” the marked (Chesbrough, 2003). This created profit, 
that in turn was used to invest in new R&D, that again created a new innovation and 
thus the circle went on and on (Chesbrough, 2003). What Chesbrough saw as an 
emerging tendency, was that this circle was 
being broken (Chesbrough, 2003). Chesbrough 
lists several reasons for the shift towards open 
innovation: 
 “(…) chief among these factors 
was the dramatic rise in the number and mobil-
ity of knowledge workers, making it increas-
ingly difficult for companies to control their proprie-
tary ideas and expertise. Another important  
Figure 1. Closed innovation (Chesbrough, 2009, 
p. 36) 
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factor was the growing availability of private venture capital, which has helped to 
finance new firms and their efforts to commercialize ideas that have spilled outside 
the silos of corporate research labs” (Chesbrough, 2003, p. 36).  
Chesbrough comes up with two figures to show the difference between open and 
closed innovation (see figure 1 & 2). 
 
Open innovation allows companies to commercialize ideas generated internally in the 
company in new markets, ideas that with closed innovation maybe never would have 
seen fruition, because they required a new marked (Chesbrough, 2003). A various 
number of pathways are used by the companies to utilize open innovation: 
 “(…) this includes startup companies (which might be financed and 
staffed with some of the company’s own personnel) and licensing agreements. In ad-
dition, ideas can also originate outside the firm’s own labs and be brought inside for 
commercializing. In other words, the boundary between a firm and its surrounding 
environment is more porous, enabling innovation to move easily between the two” 
    (Chesbrough, 2003, p. 37). 
This means that the company, instead of holding its intellectual property (IP) solely 
within the company, should find ways to profit from others using them, ex. through 
licensing agreements (Chesbrough, 2003). This also means that ideas originating out-
 Figure 2. Open innovation  
(Chesbrough, 2009, p. 37) 
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side the company, can be brought inside, and profited either on an old market, or a 
new one (Chesbrough, 2003) 
These are the mayor differences between open and closed innovation. In closed inno-
vation, the R&D department was highly trained in sorting out the “the bad proposals 
from the good ones so that they can discard the former while pursuing and commer-
cializing the latter” (Chesbrough, 2003, p. 37). This however, left a hole, with the 
ideas that may at first seem bad, but could generate profit in a different marked, or 
maybe with a different technology (Chesbrough, 2004).  
This leads Chesbrough to bring forth the contrasting principles between open and 
closed innovation:  
 
 
B) Different types of open innovation 
Inauen & Schenker-Wicki, offers three different types of open innovation, which they in 
turn have deduced from Chesbroughs writings (Inauen & Schenker-Wicki, 2011).  
These three types of innovation is visualized in figure 4, and characterized as such: 
Outside-in/Inbound open innovation 
This process entails involving a large group of outside sources in the innovation, for 
example lead users, outside stakeholders, universities, suppliers and online communi-
ties (Schroll & Mild, 2011).  Here the: 
Figure 3. (Chesbrough, 2004, p. 38) 
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 “(…) companies monitor the environment to source knowledge and 
technologies from stakeholders, such as user or suppliers and to license IP from other 
firms” 
   (Inauen & Schenker-Wicky, 2011, p. 501). 
Inside-out/Outbound open innovation 
Is a different route of innovation, and according to Inauen & Schenker-Wicky a less 
prominent method of open innovation, it is described as: 
 “ (…) companies initialize technology and IP out licensing, makes sales, 
divest and found spin-offs. The commercializing of in-house technology is the main 
purpose of this process” 
   (Inauen & Schenker-Wicky, 2011, p. 502). 
Coupled process/Mixed open innovation 
Mixed open innovation is to utilize both the outbound and the inbound aspects of the 
open innovation idea, and results in “joint ventures, whereat the focus lies in network 
usage” (Inauen & Schenker-Wicky, 2011, p. 502). This is far less used, than one of 
the aspects alone (Schroll & Mild, 2011).  
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Schroll and Mild show that the stronger a company has implemented inbound open 
innovation, it is far more likely to implement the outbound open innovation, e.i. the 
coupled process/ mixed open innovation (Schroll & Mild, 2011). 
They further demonstrate that inbound open innovation still is the preferred method 
for most companies (Schroll & Mild, 2011). This can be explained by the lower risks 
involved in inbound open innovation, as opposed to outbound innovation (Schroll & 
Mild, 2011). With outbound innovation “(…) the firm may lose possibility to capture 
the created value (…) Another potential thread lies in possible loss of the firms com-
petencies or the loss of market entry barriers (Schroll & Mild, 2011, p. 480).   
All the decisions on whether to adopt open innovation are dependent on the intensity 
of the companies R&D (Schroll & Mild, 2011). An economic crisis might force a 
company to cut costs of the R&D department, and cause them to implement a higher 
degree of outbound open innovation (Schroll & Mild, 2011). 
 
 
 
 
Figure 4. (Inauen & Schenker-Wicki, 2011, p. 502) 
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C) Open Innovation and Management in a bio-pharmaceutical 
Company 
 
The implementing of open innovation creates a demand for a new kind of manage-
ment, which so far is not very discussed in the literature (Elmquist et al, 2009). It can 
be difficult to implement open innovation as a business theory in an organization, and 
the idea of putting emphasis on innovation, instead of profiting from current technol-
ogies can be difficult to sell to employees (Elmquist et al, 2009). The unwillingness 
from the employees often comes from them being “(…) trained to think internally, 
and this tendency is strengthened by concepts such as core competences (…) (Elm-
quist et al, 2009, p. 332).  
Hyunju & Phillips have looked into the management role in open innovation in bio-
pharmaceutical companies, and found that it is a very important aspect of implement-
ing open innovation (Hyunju & Phillips, 2013). In the ever-changing pharmaceutical 
business, innovation is key to survival, and lately there has been a growing emphasis 
on external channels of knowledge and innovation (Hyunju &Phillips, 2013).This 
requires a management that has a: 
 “(…) capability of perceiving external variables and relating pertinent ones to 
the firm’s internal productive resources and/or even external resources through col-
laboration. It follows managerial innovation capability, which is the ability to make 
connections between known internal research and less well-know external resources” 
         (Hyunju & Phillips, 2013, p. 86). 
Here the focus is put on, also the management’s ability to understand and perceive 
innovation. To further this ability, Hyunju & Phillips emphasizes the importance of 
management networking, both within, and outside the company, and moreover that 
the more often a company participate in external collaborations, the better it becomes 
at utilizing the resources (Hyunju & Phillips, 2013). This is an important knowledge 
and experience, because with the rising costs of internal R&D in the bio pharmaceuti-
cal business, the reliance on externals sources have risen to reduce development time 
(Hyunju & Phillips, 2013). Hyunju & Phillips contends that when a sense of urgency 
is present, there is a greater motivation to rely on external sources, because there is 
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not enough time to build up the internal knowledge (Hyunju & Phillips, 2013). They 
go on to state: 
 “When management can perceive and conduct the optimal external collabora-
tions to gain the targeted key knowledge for the most preferred success models, this is 
management openness at the firm level” 
         (Hyunju & Phillips, 2013, p. 89). 
This management openness at firm level, is one of the keys to success in the bio-
pharmaceutical industry (Hyunju & Phillips, 2013). This requires a unique kind of 
management, who can tolerate the uncertain R&D process (which may/or may not 
lead to a sellable product), who can orientate itself towards external sources, has a 
high sense of medical ethics, and a personal flexibility (evidences by the last quota-
tion) (Hyunju & Phillips, 2013).    
 
 
 
 
2. PHARMACEUTICAL INDUSTRY 
 
A) General Drug Development 
 
The complexity and necessity of innovation in the pharmaceutical industry is only one 
step into the very complicated process of developing a new drug. Innovation brings 
about inspiration to the firm on how to proceed, however, of thousands of ideas, in-
numerous amounts are eliminated once entered in the drug development process.  
This process was however, not always as detailed and intricate as it is currently. In the 
United States and United Kingdom, for example, rigid regulations were created over 
time as a consequence of negative occurrences that made clear, the necessity for a 
more strict procedure. Large, influential organizations such as The Food and Drug 
Administration (FDA), Committee on Safety of Drugs (CSD) and the World Medical 
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Association (WMA), were created for the purpose of determining standards by which 
pharmaceutical companies must follow as well as implementing such regulations.  
 
B) Past stages of Drug Development 
 
United States  
In the United States, the first legislation, the Federal Food and Drug Act (1906) 
was concerned with the interstate transport of adulterated or misbranded foods and 
drugs. In 1938, Elixir Sulfanilamide, a solution of sulfanilamide dissolved in di-
ethylene glycol, a highly toxic solvent was responsible for the death of 105 per-
sons, many of whom were children (Brunton et al, 2005). Sulfanilamide was a 
drug used to treat streptococcal infections in tablet and powder form. The drug in 
liquid form was desired, and Harold Cole Watkins, the Massengill Company’s 
chief chemist and pharmacist, found that sulfanilamide would dissolve in diethy-
lene glycol. Before being released on the market, Elixir of Sulfanilamide was test-
ed for flavor and appearance; however no toxicity tests had been conducted. In 
this time, manufacturers had no obligation to establish drug efficacy and safety 
(U.S. Food and Drug Administration, 2015).  
  
After this tragedy, the Massengill Company was charged to only pay a fine for la-
beling their new drug “elixir”- as a misleading name. In the legal domain in the 
U.S., the 1938 Food, Drug and Cosmetics Act was passed which stated that a new 
medication would have to be properly labeled in regards to its contents and its 
amounts, and proven to be safe to the newly created agency, the FDA before the 
marketing of this medicine would be approved (Brunton et al, 2005). Neverthe-
less, still no proof of efficacy was required and non-experts were still used to test 
out the new compounds soon to be released on the pharmaceutical market.  
  
Then in 1957, the thalidomide disaster occurred and it was only then the problem 
of the severe effects of drugs on developing fetuses surfaced. The Kefauver-Harris 
drug amendments formed in 1962, in the USA, reinforced the rules for drug safety 
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and required manufacturers to prove their drugs' effectiveness (U.S. Food and 
Drug Administration, 2015). The FDA demanded manufacturers to prove their 
drug was both safe and effective after a series of rigorous testing, such as 
strengthened control of human experimentation (Healy, 1999). The FDA also re-
quired an informed consent from patients participating in clinical trials and ad-
verse drug reactions were demanded to be reported to the agency. Furthermore, 
testing for possible health threats to the fetus was mandatory and companies were 
obligated to inform the FDA of any adverse effects that occurred after a new drug 
was made available. The amendments required the FDA to establish the efficacy 
of prescription drugs as well as products that could be purchased over the counter 
(Healy, 1999).  
   
United Kingdom  
In 1963, the Committee on Safety of Drugs (CSD) was established by the UK 
Minister of Health, advising the United Kingdom Licensing Authority on the qual-
ity, efficacy and safety of medicines. The Committee had no legal powers but col-
laborated with the Association for the British Pharmaceutical Industry (ABPI) and 
the Pharmaceutical Association of Great Britain (PAGB), in examining toxicity 
tests, clinical trials, efficacy and adverse reactions, both before and during general 
use. An adverse drug reaction reporting system was established by the CSD, 
which was called the ‘yellow card’. Doctors and dentists could voluntary report 
any suspected adverse effect (Griffin, 1971).  
  
In 1964, the World Medical Association (WMA) developed its Declaration of 
Helsinki, which set standards for human experimentation. The declaration was de-
veloped as a statement of ethical principles for medical research involving human 
subjects. Subjects were required to give their informed consent before enrolling in 
an experiment. Also, proof of efficacy in clinical trials was then mandatory before 
marketing new drugs (World Medical Association, 2015). In 1967, proposals for 
new legislation to control medicines followed and The 1968 Act then emerged 
(Griffin, 1971).  
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The Act made new propositions concerning the control of medicines, for both 
human and animal use, including their promotion and sales. From September 1
st
 
1971, all medicines that were already present on the UK market had to be re-
evaluated and subsequently approved or be withdrawn. Also, all new medicinal 
products were subject to pre-marketing studies for safety, quality and efficacy be-
fore being (Griffin, 1971). A UK Licensing Authority was responsible for the 
grant, renewal, suspension and annulment of licenses and certificates for medi-
cines in the UK.   
  
In 1970, the Committee on Safety of Drugs (CSD) became the Committee on 
Safety of Medicines (CSM). Then in 1973, the UK joined the European Commit-
tee, now called the European Union. From this moment on, we can suppose that 
the UK had to follow the rules that were in place in the rest of the European 
Committee. In 2005, the Committee on Safety of Drugs became the Commission 
on Human Medicines (CHM) (Griffin, 1971).  
   
 
 
Background to drug control in the United Kingdom:   
Below is the historical perspective of attempts by the U.K government to control 
the development, highlighting the process by which regulations slowly came to 
be.  
   
The Gin Acts of the 18th century introduced the concept of control over sales and 
supply, in order to protect the community against the misuse and abuse of drugs.   
  
The British Pharmacopoeia was first published in the 19th century and over time, 
successive editions were issued. Its conditions defined standards of quality of 
drugs for human use (Griffin, 1971).  
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The Dangerous Drugs Acts (1965) recognized the dangers of drug addiction and 
introduced the concept of control of production under license, as well as strict re-
cording of sale and supply.  
  
The Pharmacy and Poisons Acts (1933), along with the introduction of the Poi-
sons Rules, elaborated the concept of control over sale and supply. Although it 
was primarily created to deal with poisons, medicines were later included. The 
control of poisons and medicines by the same rules was quite problematic; how-
ever it helped maintaining some control in the long process of transition.  
  
The Therapeutic Substances Acts (TSA) (1925) added the control of substances 
such as vaccines or sera, the purity and potency of which could not be controlled 
by chemical means. Such control demanded the use of biological standardization, 
requiring standard materials against which the products could be assayed (Griffin, 
1971). Also, the TSA recognized the importance of proper and safe conditions of 
the places in which such products were manufactured. Factory inspection and con-
trol during the process were essential in the deliberations for the issue of a license 
under the Acts and their regulations to either manufacture or import. Crucial con-
siderations of safety began to emerge thanks to these Acts which besides speculat-
ed on the purity and potency of preparations, allowed the restriction by prescrip-
tion to any medicines, which would be hazardous to the community if there were 
to be freely available.  
  
The Cancer and Veneral Diseases Acts (1917) were passed to prevent the public 
advertisement and promotion of medicines for these serious conditions. These 
both prevented fraudulent claims and protected the persons affected from inade-
quate treatment. This was the commencement of control of advertisement and 
promotional literature for medicines (Griffin, 1971).  
   
To finish, since 1992, both the United States Food and Drug Administration 
(FDA) and the European Committee for Proprietary Medicinal Products (CPMP) 
– now called The Committee for Medicinal Products for Human Use (CHMP) – 
have required manufacturers to research and characterize each aspect of a poten-
tial drug (Hargittai and Hargittai, 2006).   
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III. OPEN INNOVATION WITHIN PHARMACEUTICAL DRUG DEVELOPMENT 
 
1. STAGES OF DRUG DEVELOPMENT 
 
A. MODERN STAGES OF DRUG DEVELOPMENT    
Modern stages of drug development and drug regulations were conceived in the 
aftermath of disasters. Thus today, any potentially new drug must follow a se-
quence of steps to assure that a safe and effective drug is developed (U.S. Food 
and Drug Administration, 2015). The two principle parts in the drug development 
process are preclinical trials and clinical trials. Some 5000 compounds are used in 
preclinical tests although only about 5 will continue to clinical trials and only 1 
will be approved by the FDA to be put on the market (Brunton, 2005).  
  
 Discovery  
The discovery of a drug is a process in itself, as can be seen in figure 5. This pro-
cess is prior also to innovative initiatives. This is the stage in which an idea is 
born, after which it may be shared in one way or another, contributing to innova-
tive ideas within a company. The discovery involves identifying a target condi-
tion. Once a condition is selected, scientists must work hard to understand the tar-
get condition as much as possible along with the cause of the condition itself. This 
knowledge is essential for creating a drug which will treat the targeted problem. 
Even with all the available tools in modern research, obtaining all the necessary 
knowledge may take years and often leads to dead ends.   
Once enough knowledge is obtained, scientists use robotics and computational 
power to test hundreds of thousands of compounds against the targeted condition 
in order to determine if any might show promise. At this step, several lead com-
pounds are selected to go through further testing. A “noninferiority” requirement 
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has been put in place to assure that the drugs to be developed are at least as effec-
tive as or more effective than existing drugs for the same purpose (D’Arcy, 1993).  
 
        
 
Figure 5: Approaches to drug discovery (Waller et al., 2010)  
  
 Product Characterization  
At this stage, the promising molecule must be characterized. The molecule’s 
shape, preferred conditions for functioning, weaknesses and strengths, bioactivity, 
toxicity and bioavailability are determined using in vitro and animal studies.   
 Drug Nomenclature  
Several names exist for one drug, and although the names have been reduced to a 
minimum amount, confusion has still arisen concerning drug nomenclature 
(D’Arcy, 1993).  
 
 
 Formulation, Delivery, Packaging Development  
Formulation also involves development of the vehicle allowing precise dosing, 
this is the primary objective along with drug delivery.  
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Everything involved in storage and shipment of the drug is determined and con-
sidered at this point. The most suitable way to store and keep the drug involves 
taking into consideration heat, light and time to ensure that the drug remains ster-
ile, nontoxic and potent.   
 Pharmacokinetics and Drug Disposition  
Pharmacokinetic studies provide important feedback for scientists. This stage of 
the drug development process uses animals and the results are later compared with 
those of early stage clinical trials to check the ability and usefulness of animal 
models in predicting the efficacy and safety of a new drug (U.S. Food and Drug 
Administration, 2015).  
 
 
 
 
 
 Preclinical Toxicology Testing and IND Application  
Safety, efficacy and bioactivity are analyzed at this point in the process. This stage 
is critical to the drug’s success and therefore those responsible for regulation are 
very vigilant. The studies done at this point should support the upcoming clinical 
trials. When and if this stage is complete, an IND (investigative new drug) appli-
cation is filed to the FDA. After an IND is approved, the drug is allowed to under-
go the next steps: clinical phases 1, 2 and 3 (see figure 6) (D’Arcy, 1993).  
The testing procedures involved in the preclinical stages are developed to test the 
following:  
- Acute Toxicity  
- Sub chronic Toxicity  
- Chronic Toxicity  
- Carcinogenicity Toxicity  
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- Reproductive Toxicity  
- Developmental Toxicity  
-  Dermal Toxicity   
- Ocular Toxicity  
- Neurotoxicity   
- Genetic Toxicity  
(National Library of Medicine, 2007). 
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Figure 6: Drug development phases in the United States. Summary of the pre clinical as well 
as the clinical testing can be seen, along with the average time period for each testing process, 
the purpose of the tests at each phase, who effectuates the test and which type of patients are 
used (D’Arcy, 1993).  
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Clinical Trials  
The tests involved in clinical trials have a duration of 2-10 years (average is 5-7 
years) (Brunton, 2005). Clinical trials consist of the following phases and if suc-
cessful, the manufacturer may issue a new drug application (NDA) for FDA ap-
proval.   
• Phase I Clinical Development (Human Pharmacology)  
Phase I has duration of at least one year (Brunton, 2005).  
• Phase II Clinical Development (Therapeutic Exploratory)  
Phase II has a duration of at least 2 years and evaluates drug efficacy, safe-
ty and side effects in 100-400 patients suffering from the disease to be 
treated (Brunton, 2005).   
• Phase III Clinical Development (Therapeutic Confirmatory)  
This phase evaluates safety and efficacy in large patient populations. About 
10003000 carefully selected patients receive a new drug at this stage 
(Brunton, 2005).  
▪       Phase IV- Post marketing surveillance  
Phase IV Clinical trial is in progress for a new drug after the drug has 
passed all other phases in clinical development and after being approved by 
such organizations as the FDA or the European Medicines Agency (EMA). 
This phase is used to determine the safety and efficacy of the drug over a 
more extensive period of time and in a more diverse “test” group. Since the 
drug is being used more broadly at this point, a number of unanticipated 
beneficial and adverse effects are detectable (D’Arcy, 1993).   
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As a conclusion, the different stage of drug development, starting from the dis-
covery of a new drug to the clinical trials conducted on this drug can be resumed 
in the following figure (7): 
  
Figure 7: The development of a new drug to the point at which a license is approved. Post-
marketing surveillance will continue to add data on safety and efficacy (Waller 
et al., 2010)   
 
 
 
 
 
 
 
 
 
 
 
 
Spring 2015: Minna Munch- Jensen and Ursula Izabel Waltemath 
28 
 
2. DRUG RESEARCH AND DEVELOPMENT DEPARTMENT  
 
 
An organized form of open innovation distinguishes a firm from its competitors. The 
correct usage of this information can lead to profitable advantages. A crucial part of 
this organization is the presence of a strong drug research and development depart-
ment (drug R&D). The R&D department incorporates (open) innovative strategies, 
such as acquiring knowledge from external sources.  (Schroll A., 2011) 
 
 
Figure 8 (Innovation Management, 2011) 
 
As can be seen in figure 8, Universities and research institutes are representing the most important 
sources of knowledge for innovating companies, while start-ups, competitors, and innovation 
intermediaries are less popular sources. 
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3. PHARMACEUTICAL SOURCES FOR OPEN INNOVATION 
As mentioned earlier open innovation is a term, that still lacks scholarly exploration, 
especially systematic and longitudinal investigation (Chiaroni et al., 2009). Chiaroni 
et al., has conducted a thorough analysis of the implementation of open innovation in 
the bio-pharmaceutical industry, which rely on an expert panel to pin-point the phases 
of drug development, and a review of 20 top international bio-pharmaceutical firms 
annual report, regarding R&D and innovation (Chiaroni et al., 2009). 
In their work with the expert panel, they come up with the following phases of drug 
development, previously described in more detail: 
(1) Target identification and validation 
The purpose of this phase, is to identify the gene, protein, or sequence believed to be 
connected with the pathogenic of a given disease. Following this is the investigation 
in to the found target and define how it relates to the human body as a whole, and if 
there are any IP’s pertaining to the target (Chiaroni et al., 2009). 
(2) Lead identification and optimization 
Here the scientist’s identify the “compound that has the desired effects in treating the 
selected disease (…)” (Chiaroni et al., 2009, p. 293). This will ultimately act as the 
active substance in the drug. 
(3) Pre-clinical tests 
In this part of the development, the drug is tested in vivo and though this the “mecha-
nisms of absorption, distribution, metabolism, excretion and toxicology” (Chiaroni et 
al., 2009, p. 293) of the drug is determined. Before the drug can move on to next 
phase, a approval by the authorities is needed (Chianori, 2009).  
(4) Clinical tests 
Here the drug is finally tested on humans, in phase I first on a small selction of indi-
viduals (20-80 people). In phase II the range of test persons are widened (100-300 
people, and finally in phase III the drug is given to even more persons (1000-3000 
people), this is done to confirm any side effects. if all three phases has an agreeable 
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outcome, the authorities clears the drug, and it can be put on the market (Chiaroni et 
al., 2009). 
(5) Post-approval activities 
This is the phase where the drug is produced, marketed and sold. Further more this 
phase include the continued monitoring of the drug’s performance, and the occurrence 
of risks, side effect etc. (Chiaroni et al., 2009). 
 
 
After agreeing in these stages of drug development, the expert panel divided the drug 
discovery and development phases in to two macro-phases (Figure 9), these consist of 
generation, and exploitation (Chiaroni et al., 2009). In the generation phase is where 
inbound open innovation most commonly takes place: 
 “(…) biotech companies enter in contact with external organizations for lever-
aging on their innovation efforts and accessing heir highly specialized knowledge and 
competences” 
              (Chiaroni et al., 2009, p. 294). 
In the exploitation phase, is where the outbound open innovation takes place: 
 “(…) biotech firms generally open up to external organizations for commercial-
ly exploiting the results of their innovation activities”  
Figure 9. The two macro-phases in pharmaceutical biotech drug discovery and development process  
(Chiaroni et al., 2009, p. 294) 
 
 
 
( 
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        (Chiaroni et al., 2009, p. 294). 
The expert panel identified the transit from pre-clinical tests and clinical tests was 
what separated generation and exploitation, but also allowed for some overlapping (as 
represented by the medium grey area in figure…), this is due to the uncertainty con-
nected with drug development, it is only when the clinical tests is completed, and the 
drug approved a company can start to commercialize a drug, and thereby involve ex-
ternal sources for commercializing (Chiaroni, et al., 2009). This means that commer-
cial exploitation sometimes starts before the clinical tests is done, this happens by out-
licensing of a drug not fully tested, or the in-licensing of a drug that has completed 
phase I of clinical tests (Chiaroni et al., 2009). 
Chiaroni et al., with the help of the expert panel, was also able to identify which 
modes the orginisations utilized these two modes of open innovation. (Chiaroni et al., 
2009) 
A) Open innovation for the generation of innovation 
 - Collaboration for the generation of innovation. Here the company form 
partnerships with other biotech firms, pharmaceutical firms, universities or govern-
mental research centers to facilitate the validation of a genetic target (Chiaroni, et al., 
2009). 
 - Purchase of scientific services. To complete the lead optimisation of the ac-
tive substance in the drug, the biotech firm can externalise this phase to a specialized 
provider (Chiaroni et al., 2009) 
 - In-licensing. The firm licenses the right to use another firms drug, it can also 
be acquired from a university (Chiaroni et al., 2009).  
B) Open innovation modes for the exploitation of innovation 
 - Collaborating for the exploitation of innovation. Here the biotech firm en-
ters collaboration with a biotech firm, usually a big pharma, to get access to a need 
asset, that being either some product capacity or some distribution channels etc. (Chi-
aroni et al., 2009). 
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 - Supply of scientific services. The firm in this instance provide technical or 
scientific services to a third party, usually another biotech firm (Chiaroni et al., 2009). 
 - Out-licensing. As opposed to in-licensing, the firm here out-licenses a drug it 
has developed, to a third party, usually another biotech firm (Chiaroni et al., 2009). 
This is finally put into figure 10. 
  
 
 
 
 
 
 
 
 
 
Figure 10.  Open innovation modes and their position along the phases of the drug discovery and development 
process (Chiaroni et al., 2009, p. 296). 
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Method 
The theoretical basis for the methodology used in this paper is based on the methods 
developed in Ib Andersen’s book “Den Skinbarlige Virkelighed” (2002). This book 
concerns philosophy of science and scientific methods useful in scholarly investiga-
tion (Andersen, 2002).  
Here he introduces the term kundskabsmæssige formål,(Andersen, 2002) which in the 
following will be translated to knowledge purposes. 
He contends that the chosen methodology must be based on ones problem formula-
tion, the field of investigation, and the knowledge purpose of the paper (Andersen, 
2002). 
Andersen present five different knowledge purposes (translated from the Danish text 
by us) (Andersen, 2002, p. 22): 
(1) The descriptive 
(2) The explorative/problem identifying/diagnosing 
(3)  The explanatory/perceptive 
(4) The problem solving/normative 
(5) The interview oriented 
These five different knowledge purposes allows the researcher to produce different 
types of knowledge, and is it especially the difference in the knowledge produced that 
Andersen underlines (Andersen, 2002).  
 
Here follows a short summary of the five different knowledge purposes. 
 
The descriptive knowledge purpose  
With this purpose, the researcher refrain from understanding or explaining a finding 
or problem, one merely wishes to describe a given issue (Andersen, 2002). Here 
Andersen mentions exit polls and its like, which purpose is not to identify why people 
vote they do, but only how they vote (Andersen, 2002) 
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The explorative/problem identifying/diagnosing knowledge purpose 
Here the researcher wishes to explore an area more or less un-investigated in the 
literature; this usually pertains to little known phenomena that the researcher wishes 
to identify problems and questions connected to the phenomena (Andersen, 2002). It 
is important to bear in mind that the purpose with these papers is not to solve the 
problem, solely to identify it (Andersen, 2002). 
 
The explanatory/perceptive knowledge purpose 
Papers with these purposes usually focus, not on collection data, but analyzing 
already collected data (Andersen, 2002). There is a difference between an explanatory 
and a perceptive purpose, the first is mostly found in scientific papers, while the latter 
is more predominant in the human sciences (Andersen, 2002). 
 
The problem solving/normative knowledge purpose 
Here the researcher tries to find solutions to problems, maybe found in a explorative 
paper (Andersen, 2002). This is done by analyzing a issue, and on the basis of the 
analysis, the researcher wish to find alternative ways to go about things (Andersen, 
2002) 
 
The interview oriented knowledge purpose 
In this approach, the researcher takes one step further from the problem solving 
knowledge purpose, and actually implement the suggestions and solutions found in a 
problem solving/normative knowledge purpose paper (Andersen, 2002). 
 
Our knowledge purposes 
All of the above mentioned knowledge purposes could be used to investigate the area 
of open innovation in bio-pharmaceutical firms. However, as it becomes apparent that 
the term, open innovation, is very under-investigated in a practical setting, some 
avenues becomes closed. It is therefor not practical for us to use the descriptive 
purpose, in that it offers to little leave room for conclusions and discussion. 
Furthermore the problem solving/normative knowledge purpose seems to be closed 
of, seeing that the subject of open innovation, especially in a bio-pharmaceutical 
setting is to unexplored to allow for a thorough examination of previous explorative 
papers. 
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On the same ground, the interview oriented purpose is not possible to pursue yet, but 
one can hope the problem becomes analyzed enough for this to happen. 
 
This leaves us with the explorative/problem identifying/diagnosing knowledge 
purpose and the explanatory/perceptive knowledge purpose. Both can be used to 
examine the phenomena of open innovation in a bio-pharmaceutical firm, due to the 
little knowledge pertaining to the issue. we have chosen to adopt both purposes, in 
that we wish to identify the problems/challenges concerned with open innovation, but 
will rely on data collected from other literary sources, as opposed to data collected 
first-hand by us. 
 
Collection of literary data 
Our collection of data was carried out by searching the databases: 
- ProQuest 
- Google Scholar 
- EBSCOhost 
- SCOPUS 
- SciFInder 
- Den danske forskningsbase (previously DANDOK) 
 
We made a preliminary search, using the term “open innovation”, either in the title, 
keywords, or abstract. This provided us with a vast number of papers that had to be 
sorted out. We had to make a basic review of the search results, to weed out the hits 
that only peripherally touch upon the subject of open innovation.  
After an overall review of the material, we identified the main scholarly contributors 
on the subject of open innovation, foremost Henry W. Chesborough. This prompted us 
to a make a search in the same databases, using “Henry W. Chesborough” as the 
search term. This was done to get a thorough understanding of the origin of open 
innovation, and to be able to track the theoretical developments in the field. 
We made a third search in the same databases, using the term “open innovation in bio-
pharmaceutical”. This was done to narrow down the hits, and to investigate how well-
researched the crossing between open innovation and bio-pharmacy are. This was also 
done to get an understanding of how open innovation can be imposed on the bio-
pharmaceutical business. 
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Lastly, searches were made using terms such as “Drug development stages”, “Drug 
regulations” and “drug innovation”. This was made on data bases such as SCOPUS 
and SciFInder. The searches provided specific articles which clearly defined the 
stages of drug development, where we were able to analyze the complexity of the 
entire process of which open innovation results in.  
 
 
IV. DISCUSSION 
 
The field of open innovation is a field that still lacks a considerable amount of schol-
arly investigation, which has become clear during this project. This is mostly due to 
the relatively newness of the term, but also that it seems it still has not been tested in a 
practical setting.  
 
However, from what we have found in the literature, we are able to bring some inter-
esting problems and challenges that face open innovation, particularly in a bio-
pharmaceutical setting, and how it has been adopted. 
 
When we look at the issues Elmquist et al. and Hyunju & Phillips bring up, it be-
comes clear that a new form of management is needed to make open innovation work 
in practice. It is pointed out, that open innovation as a business philosophy is en-
trenched on how willing the management is to engage in change and the new business 
ways open innovation brings with it. Furthermore Elmquist et al. argues that, the em-
ployees need an engaged management, to help them transit from a focus on core com-
petencies and the tendency to value secrecy. 
 
Hyunju & Phillips spend a good deal of their paper, contemplating what kind of man-
agement open innovation in a bio-pharmaceutical firm requires. They show,  that an 
emphasis on managerial networking, both externally and internally in the firm, helps 
the firm dealing with external sources greatly, this is in part due to the fact, that the 
more experience a firm has with dealing with external sources, the more it gets out of 
it.   
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It has furthermore been shown, through especially Hyunju & Phillips, but also by 
Chesbrough and Inauen & Schenker-Wicki, that a range of external sources contribute 
to open innovation. Even though both Inauen & Schenker-Wicki, and Chesbrough 
investigate the term open innovation from a quite general view-point, several of their 
findings can be used to underpin the claims of Hyunju & Phillips.  
 
First of all, there are Chesbrough’s distinctions between the different kinds of open 
innovation, further developed by Inauen & Schenker-Wicki. What Hyunju & Phillips 
find, is that these distinctions can be found in practice, and are being used by bio-
pharmaceutical managers and firms. 
 
As an extension to this, can be seen the practical external sources found in Hyunju & 
Phillip’s article, they show, that not only is outbound and inbound innovation present 
in the bio-pharmaceutical business, but it takes more practical forms, forms 
Chesbrough predicted. 
 
Hyunju and Phillips show in their article, that both out/in-licensing can be seen in 
different phases of the drug development, and that the changes in the make-up of the 
R&D department, has meant that spin-off ventures is occurring more often. This all 
falls in line with what Chesbrough initially predicted, and goes to show the versatility 
of the use of open innovation.  
 
Another interesting point, that Hyunju & Phillips brings to bear, that the adaptation of 
open innovation, actually insures a greater collaboration between firms, as a result of 
the rising occurrence of out/in-licensing, combined with the buying and selling of IP’s 
not fully developed.       
 
 
 
V. CONCLUSION 
 
Both Elmquist et al. and Hyunju & Phillips show not only the importance of a new 
approach to management and open innovation, but also that it is an important contrib-
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uting source to a successful implementation of open innovation. And it is certain that 
the right, and flexible management, is a key source to the implementation as sustain-
ing of open innovation, not only in bio-pharmaceutical firms, but in general. 
As to the more specific external sources for open innovation in a bio-pharmaceutical 
firm, these can be found in the correlation between the theoretical level (Chesbrough 
and Inauen & Schenker-Wicki) and the practical level (Hyunju & Phillips), which 
shows that there is, at least evidence for, the theory of open innovation can be super-
imposed onto the bio-pharmaceutical business. Most emphasize can be placed here, 
on the collaboration between bio-pharmaceutical firms, and the importance of a mu-
tual beneficiary relationship between different firms. Here there seems to be most 
evidence for the use of out/in-licensing, and the way it has introduced new players 
onto the marked, that develop a drug to a certain stage, and then sell it off to bigger 
firms, that in turn make sure there pipe-line is sufficiently stocked for the future. 
There is some mention of collaborations between bio-pharmaceutical firms and uni-
versities, but the mention is so scarce, that is it not sufficient to conclude to how big 
of degree this take place, and if they are indeed beneficiary for the parties involved. 
There is also some mention by Chesbrough of the use of the user, and consumers, so 
to speak. There is no mention of bio-pharmaceutical firms using the consumers as an 
external source to their drug development, but this might be due to straight regula-
tions on the area of how pharmaceutical firms can advertise to the consumer. 
 
As it has been apparent throughout this article, the subject of open innovation within 
the bio-pharmaceutical industry is simply yet not thoroughly examined. This had pre-
vented us from being able to make any definite conclusions as to the external sources 
pertaining to open innovation in the bio-pharmaceutical industry, but some general 
tendencies occur. 
The use of out/in-licencing, the use of spin-off ventures, the buying and selling of 
unfinished drugs, to be finished and sold in other firms.      
 
 
 
VII. PERSPECTIVES 
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The many uncertainties surrounding the future, and even present, of open innovation 
in the bio-pharmaceutical industry opens up, for a long range of potential projects to 
be made. It could for example be beneficiary, and probably very interesting to inves-
tigate in more depth, what open innovation demands of the management in question. 
How it can be best implemented, and also what potential downsides open innovation 
brings with it. 
Another subject for a future projects could be a thorough, practical, investigation into 
how open innovation in the bio-pharmaceutical industry is implemented, and which 
specific sources contribute to make it possible. This would probably be helpful to a 
greater understanding of what open innovation demands of both the management, but 
also the employees. 
Most of all it can be said, that the subject of open innovation, is a vastly interesting 
one, but one that still remains anchored in mainly theoretical terms, and it needs to be 
brought down on the practical plane, to fully prove it’s usability, this is where the 
future scholarly research must be done.       
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